MERCK & CO, INC. for MERCK & CO INC
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 19, 2010 | $3,220,000 | Replaced |
| 1st Quarter - Amendment (this page) | May 17, 2011 | $3,220,000 | Yes |
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs (no specific legislation); efforts to ensure appropriate access to vaccines under Medicare (H.R. 3200; S. 1796; H.R. 3590); Expansion of, or increase in, Medicaid rebates (H.R. 3200; S. 1796; H.R. 3590; H.R. 4872)
| Lobbyist | Covered position, as disclosed |
|---|---|
| VICTORIA BLATTER | — |
| ERIN DARLING | — |
| ANNE ESPOSITO | — |
| JANE HORVATH | — |
| ELI JOSEPH | Leg. Asst. White House Office of Leg. Affrs. |
| LAURIE MICHEL | — |
| JASON BENJAMIN VAN PELT | — |
Budget/Appropriations BUD
Increased funding for CDC's National Immunization Program (Sec. 317 program); increased funding for AIDS Drug Assistance Program (ADAP) (FY11 Budget, LHHS Appropriations bill)
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURIE MICHEL | — |
Financial Institutions/Investments/Securities FIN
End use of derivatives (no specific bill)
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON BENJAMIN VAN PELT | — |
Taxation/Internal Revenue Code TAX
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation); renewal and expansion of the R&D tax credit (H.R. 422; S. 1203)
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON BENJAMIN VAN PELT | — |
Copyright/Patent/Trademark CPT
Apportionment of damages and post-grant review of patents (S. 515; H.R. 1260)
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURIE MICHEL | — |
Health Issues HCR
Rx drug importation into the US, other than by drug manufacturer (no specific bill); requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill); promote public/private partnerships for comparative effectiveness assessments (S. 1213); Physician Payments Sunshine Act of 2009 (S. 301); health care reform; increasing coverage of uninsured; coverage of preventative services; including immunizations; expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization; maintaining market-based, private sector health care delivery system (H.R. 3200; S. 1679; S. 1796; H.R. 3590; H.R. 4872)
| Lobbyist | Covered position, as disclosed |
|---|---|
| G LAWRENCE ATKINS | — |
| VICTORIA BLATTER | — |
| ERIN DARLING | — |
| ANNE ESPOSITO | — |
| JANE HORVATH | — |
| ELI JOSEPH | Leg. Asst., WH Office of Leg. Affs. |
| LAURIE MICHEL | — |
| ANGELA M STEWART | Leg. Counsel, Leg. Asst., Sen. John Warner |
| JASON BENJAMIN VAN PELT | — |
Medical/Disease Research/Clinical Labs MED
Approval and regulation of biosimilars (H.R. 1427; H.R. 1548; S. 726; H.R. 3200; S. 1679; H.R. 4872)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERIN DARLING | — |
| ELI JOSEPH | Leg. Asst. White house Off. of Leg Affairs |
| LAURIE MICHEL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.